contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-physitrack-q4-review-strategic-reset-complete-pivot-to-pure-saas-growth-acceleration

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Physitrack operates in the healthcare sector and specializes in physiotherapy. The product portfolio includes digital healthcare offerings for companies via SaaS solutions. In addition to the main business, personal service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe and North America. Physitrack was founded in 2012 and is headquartered in London.

Physitrack aloittaa omien osakkeiden ostot, kun kassavirta on vihdoin kunnossa ja arvostus alhaalla    Physitrack PLC announces intention to implement share buyback program Physitrack’s Board of Directors has approved the intention to implement a share buyback program (the “SBB”), subject to lender consent and prevailing market conditions. London, February 20. 2026 Physitrack PLC (Nasdaq First North: PTRK) (“Physitrack” or the “Company”) today announces that its Board of Directors has approved the intention to implement a share buyback program (the “SBB”), subject to lender consent and prevailing market conditions. The Board believes that, following the Group’s strengthened profitability, improved margin profile and sustained positive free cash flow, it is appropriate to establish a framework that enhances capital flexibility and supports long-term shareholder value creation. The Company intends to utilise the existing shareholder authorisation granted at the Annual General Meeting to repurchase up to 10 per cent of the Company’s issued share capital. Any repurchases would be funded from operating cash flow and distributable reserves and would not involve drawings under the Company’s revolving credit facility. The SBB provides the Company with flexibility in capital allocation. Repurchased shares may be cancelled to reduce the number of shares outstanding or held in treasury for potential future use, including possible share-based incentive arrangements. No share-based incentive plan has been approved at this time. Henrik Molin, CEO and co-founder, commented:  “Physitrack exits 2025 with materially improved cash generation, stronger margins and a more focused operating model. Establishing a share buyback framework reflects the Board’s confidence in the business and its commitment to disciplined capital allocation. We view buybacks, like dividends, as a legitimate shareholder value tool. This program provides flexibility to optimise our capital structure while continuing to invest in growth.” Implementation of the program remains subject to approval from the Company’s banking partner. The Board does not currently anticipate any impediment to obtaining such approval. The timing, size and execution of any repurchases will remain at the discretion of the Board and will be conducted in accordance with the EU Market Abuse Regulation (MAR), applicable safe harbour rules and Nasdaq First North Premier Growth Market requirements. No share repurchases have been made as of the date of this announcement. Further updates will be provided in accordance with applicable disclosure requirements

Aika odotuksien mukainen Q4 katsaus. Viralliset ja tarkistetut luvut sitten myöhemmin. Kasvua tarvitaan, kannattavuus olennaisesti parempi.            storage.mfn.se              pdf-report-physitrack-plc-unaudited-fy2025-trading-update-and-preliminary-results.pdf                             CEO-Henrikin haastattelu  https://vimeo.com/1159117322/60b2488cb7?fl=tl&fe=ec Tässä muuten hyvää tiivistystä aktiiviselta seuraajalta, erityisesti huomiot US-markkinan osalta.  https://x.com/HappyZubi/status/2015730831482916923?s=20 edit:  Vielä Redeyn kommentit jatkoksi:                   redeye.se              Physitrack (Q4 preliminary figures): Margins improving, but growth stalled    Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our expectations. The main highlights include continued margin expansion and improved free cash flow (FCF

Redeyn Q4 / 2025 ennakot                  redeye.se              Physitrack (Q4 Preview): Profitability strength amidst muted growth    Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 January, followed by the Q4 and Annual Report on 27 February. We expect the key highlights to be continue                             Tältä vuodelta lopetettuja ja myytyjä alhaisemman katteen liiketoimintoja, joiden osalta liikevaihto laskemassa.  Näiden seurauksena myös liikearvon poistoja, mikä näkyy tuloksessa / EPS:issä. Kassavirtaan ei kovin olennaista vaikutusta enää, mutta näkyy sitten raportoidussa tuloksessa.  Significant adjustments of EUR 5.1m Investors should prepare for significant “below-the-line” movements this quarter. However, we expect only a minor portion—approximately EUR 0.4m—to affect cash flow. Total adjusting items are expected to be roughly EUR 5.1m, primarily driven by a balance sheet cleanup following the divestment of Fysiotest and the closure of clinic operations:  • Impairment of Goodwill/Intangibles: EUR 3.3m (non-cash operating expense).  • Derecognition of Assets: EUR 1.6m (non-cash operating expense, related to goodwill and intangibles).  • Restructuring Fees: EUR 0.4m (cash-effecting costs related to the divestment of Fysiotest and the closure of clinic operations).  Isompaa kauppaa ei ole julkaistu, joten mitään merkittävää kasvua ei ole odotettavissa. Itse seuraan tässä vaiheessa enemmän kassavirtaa ja kommentteja US-markkinan laajentamisesta. Toki myös EBITDA tässä kohtaa, että kannattavuuden kehitys palautuu odotetulle uralle.

Wellness’n uudelleen järjestelyt viedään päätökseen, klinikat suljetaan ja fokus SaaS -hommiin  **  Physitrack announces strategic restructure of Wellness division to focus on high-margin SaaS growth in 2026** London, 24 November 2025 – Physitrack PLC (“Physitrack”) announces the continued restructuring of its Wellness division as part of the Group’s strategy to focus on high-margin, recurring-revenue software in 2026. As part of this restructuring, the Group will exit human-intensive, lower-margin care operations in Wellness and focus on its core SaaS platforms in Physitrack and Champion Health. This includes the divestment of Fysiotest / Champion Health Nordics and the closure of all remaining clinics in Champion Health Plus. This strategy is a continuation of the work initiated in 2024 and 2025 to focus the Group, improve profitability and reinforce Physitrack as a SaaS-led business. The divestments and closures do not affect Physitrack’s core SaaS platforms, where demand and growth opportunities remain strong heading into 2026. Summary highlights (pro forma YTD to 30 September 2025) Had the divestment and clinic closures taken effect from 1 January 2025:  Revenue impact: –€1.0m Adjusted EBITDA impact: +€0.2m Adjusted EBITDA margin: 38%, compared with the reported 32% Cash impact: +€0.1m Recurring revenue mix: would have been 95% of Group revenue (vs 86% reported)  These changes strengthen the Group’s financial profile, improve revenue visibility and support a more scalable, software-driven growth trajectory into 2026 and beyond. Intended divestment of Fysiotest AB / Champion Health Nordics  Physitrack has signed Heads of Terms with existing management for a potential divestment of Fysiotest Europa AB / Champion Health Nordics through a management buy-out. Completion, subject to contract, is targeted for the end of December 2025.  Expected consideration: €1 Estimated disposal costs (adjusting items): approx. €0.1m Goodwill and intangible assets to be derecognised: €1.6m (carrying value at 30 September 2025)  Contracts relating to the Champion Health Swedish platform will remain with Physitrack’s Champion Health business, with Nordic sales activities now led from London. As part of the finalisation of the SPA, Physitrack expects to enter into a reseller distribution agreement with existing management to continue selling the platform in the region.  2) Champion Health Plus – closure of clinic operations  Physitrack will close the remaining Champion Health Plus clinics and retain the asset-light elements of the business, including the National Network offering and the Nexa digital triage platform.  Estimated closure-related costs (adjusting items): approx. €0.2–0.3m Impairment of related goodwill and intangibles: €3.3m (carrying value at 30 September 2025)  The retained activities align fully with Physitrack’s SaaS and digital health strategy, supporting scalable and margin-accretive growth. Management commentary  Henrik Molin, CEO and Co-founder of Physitrack, commented: “These actions complete the Wellness pivot to pure-play SaaS we started in 2024. By exiting labour-intensive care operations and focusing fully on our SaaS and digital platforms, we position Physitrack for sustainable, high-margin growth in 2026 and beyond.”

Redeyn laajemmat kommentit                   redeye.se              Physitrack (Q3 Review): Staying on track with solid profitability and cash flow    Redeye has updated its estimates following Physitrack’s Q3 2025 report, which was broadly in line with expectations. The quarter showed continued margin strength and solid cash flow generation, with                             Ja OT Analytics vastaava  (yksityinen sijoittaja, joka seuraa Physitrackia ja on isona omistajana mukana)            preview.mailerlite.io              Physitrack | Stabilt, men utan lyft                              Lyhyesti: kuten omakin kommentti yllä. Kassavirta ja kannattavuus on nyt kunnossa. Kasvua tarvitaan Wellness -puolelle, jotta oikea arvo tulee esille. treidaa n. ~50% alennuksella verrokkeihin. Edit 24.10. lisätään vielä Lind Researchin läpikäynnit tänne                   Lind Research              Physitrack (PTRK): Market Misses the Cash-Flow and SaaS Quality Shift -...    Physitrack’s Q3 confirmed steady progress in its SaaS transition, with EBITDA up 25% and free cash flow turning positive for a fourth consecutive quarter. Lifecare remains the core profit driver, growing ARR 13% YoY and delivering sector-leading...

Matka jatkuu hyvän Q2:n jälkeen samaan suuntaan. Kannattavuus ja kassavirta kehittyy, heikkokatteisten klinikoiden sulkeminen pienentää liikevaihtoa odotetusti. Uudellenjärjestelyjen kertakulut näkyy toki vielä. Kertakulut pois luvuista jatkossa ja pari isompaa kauppaa Wellness -puolelle, niin arvostuksen uudelleenhinnoittelulle alkaa olla hyvät perusteet  Koko raportti:            storage.mfn.se              q3-2025-interim-report-final.pdf                             Physitrack PLC – Interim report: January – September 2025   Summary for the period  Third quarter: 1st July – 30th September 2025 Based on Alternative Key Performance Measures, the Company’s key financial highlights for the period are summarised below. Performance broken down per division is provided later in this release.   Pro forma revenue, following planned low margin revenue reduction, has increased by 6 per cent to generate total sales of EUR 3.5m (EUR 3.3m). This grew by 9 per cent on a constant currency basis.   Lifecare achieved a 13 per cent revenue increase, reaching EUR 2.9m. When assessing organic revenue free from currency fluctuations this was a 17 per cent revenue increase, reaching EUR 3.0m.   Wellness revenue declined by 18 per cent on a pro forma revenue basis to EUR 0.6m. On a constant currency basis, revenue declined by 16 per cent. This is a reflection of unprofitable clinic closures as well as planned expiry of legacy founder-linked contracts as the division refocuses on higher margin enterprise customers.   Subscription revenue increased 7 per cent (EUR 0.2m) to EUR 3.0m and now makes up 88 per cent of total group revenue, an increase from 82 at Q3 2024.   Adjusted EBITDA of EUR 1.2m (EUR 0.9m) was generated resulting in a Pro forma adjusted EBITDA margin of 33 per cent (28 per cent).   Pro forma adjusted EBITDA less CAPEX of EUR 0.4m (EUR 0.1m) was generated resulting in an Pro forma adjusted EBITDA margin less CAPEX margin of 11 per cent (2 per cent). This was split between Lifecare of EUR 0.7m / 23 per cent margin and Wellness of EUR -0.04m / -7 per cent margin.   Adjusted operating loss of EUR 0.1m (loss EUR 0.2m) was generated resulting in a margin of -2 per cent (-6 per cent).   Adjusted ordinary and diluted profit per share totalled EUR -0.01 (EUR (0.02)).   Cashflow generated from operations before the payment of adjusting items equalled EUR 1.4m (EUR 0.8m).   Free cash flow for the quarter was a net inflow of EUR 0.4m (outflow EUR 0.4m).    Edit: lisätään tähän vielä Redeyn pikakommentit, odotuksiin meni myös heidän mukaan                   redeye.se              Physitrack (Q3 Initital take): Stable quarter with continued margin expansion...    Redeye sees a Q3 report from Physitrack largely in line with our expectations. The company continues to execute well on its margin expansion path, generating solid free cash flow. We are not too conc

Redeyn ennakot Q3:lle 21.10. Kannattavuus pitäisi olla parantumassa, Lifecaressa ollut hinnankorotuksia. Mutta Wellness odottaa isompia sopimuksia em. vakuutusyhtiödiilin lisäksi.                   redeye.se              Physitrack Q3 Preview: Profitability momentum continues despite Wellness...    Redeye comments on Physitrack ahead of its Q3 results, due on 21 October (rescheduled from 31 October). We expect continued profitability improvements in Q3 2025e, driven by price increases in Lifeca

Physitrack

Redeye’s analyst just published a Research Update on Physitrack.Click here to read the articleMake sure to add Physitrack to your Watchlist at Redeye and our analysts will notify you if anything...

<div class="mfn-body"><p>Redeye’s analyst just published a Research Update on Physitrack.</p><p><strong><a rel="noopener" href="https://www.redeye.se/research/1155234/physitrack-q4-review-strategic-reset-complete-pivot-to-pure-saas-growth-acceleration?utm_source=MFN&amp;utm_medium=pmcour">Click here to read the article</a></strong></p><p>Make sure to add Physitrack to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.</p><p>This is a press release from Redeye - Research Powered Investment Banking.&nbsp;<a rel="noopener" href="http://www.redeye.se/">www.redeye.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/48012686-6ae3-4e83-83bb-0109403ad6e6/physitrack-q4-review-strategic-reset-complete-pivot-to-pure-saas-growth-acceleration.pdf" class="mfn-generated mfn-primary">Physitrack (Q4 Review): Strategic reset complete; pivot to pure-SaaS growth acceleration</a></p></div>